.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,812,233

« Back to Dashboard

Details for Patent: 6,812,233

Title: Therapeutic nucleosides
Abstract:The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.
Inventor(s): Liotta; Dennis C. (McDonough, GA)
Assignee: Emory University (Atlanta, GA)
Filing Date:Jan 15, 1998
Application Number:09/007,502
Claims:1. A method of treating an HBV infection in a human having an HBV infection comprising orally administering a pharmaceutical composition suitable for oral administration containing an effective HBV infection treatment amount of a cis isomer of the compound of formula (I) ##STR5##

or a pharmaceutically acceptable salt thereof to said HBV infected human.

2. The method of claim 1, in which the compound or salt is administered in a tablet or capsule.

3. A method of treating an HBV infection in a human having an HBV infection comprising injecting said HBV infected human with a sterile liquid pharmaceutical composition containing an effective HBV infection treatment amount of a cis isomer of the compound of formula (I) ##STR6##

or a pharmaceutically acceptable salt thereof.

4. A method of treating an HBV infected host which comprises administering an effective HBV treatment amount of the compound ##STR7##

or a pharmaceutically acceptable salt thereof to said HBV infected host.

5. A method of treating an HBV infection in a host which comprises administering an effective HBV treatment amount of the compound (.+-.)-cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)fluorocytosine to said HBV infected host.

6. A method of limiting Hepatitis B virus production in a plurality of human cells containing said virus which comprises the step of applying to said cells containing said virus an amount of the compound cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine sufficient to limit production of said virus.

7. A method for the prophylaxis of an HBV infection in a host which comprises administering an effective amount of the compound (.+-.)-cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)fluorocytosine to said HBV infected host.

8. A method for theMtreatment of a hepatitis B infection in an infected host which comprises administering an effective HBV treatment amount of the compound cis-(2-hydroxymethyl)-1,3-oxathioan-5-yl)-5-fluorocytosine substantially in the form of one optical isomer or its pharmaceutically acceptable salt to the hepatitis B infected host.

9. A method for the treatment of a hepatitis B infection in an infected host which comprises administering an effective HBV treatment amount of a compound consisting essentially of one optical isomer of cis-(2-hydroxymethyl)-1,3-oxathioan-5-yl)-5-fluorocytosine substantially in the form of one optical isomer or its pharmaceutically acceptable salt to the hepatitis B infected host.

10. The method of claim 8, wherein the optical isomer is the (-)-optical isomer.

11. The method of claim 8, wherein the optical isomer is the (+)-optical isomer.

12. The method of claim 9, wherein the optical isomer is the (-)-optical isomer.

13. The method of claim 9, wherein the optical isomer is the (+)-optical isomer.

14. The methods of claims 9-13 wherein the host is a human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc